Chiasmatic gliomas with diencephalic syndrome in infants: challenges in the diagnosis and treatment
- Authors: Papusha L.I.1, Merishavyan A.A.1, Zaytseva M.A.1, Degtyarev V.A.1, Alymova Y.A.1, Druy A.E.1,2, Karachunskiy A.I.1
- 
							Affiliations: 
							- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
- Research Institute of Medical Cell Technologies
 
- Issue: Vol 21, No 4 (2022)
- Pages: 118-123
- Section: CLINICAL OBSERVATIONS
- Submitted: 17.01.2023
- Accepted: 17.01.2023
- Published: 26.12.2022
- URL: https://hemoncim.com/jour/article/view/683
- DOI: https://doi.org/10.24287/1726-1708-2022-21-4-118-123
- ID: 683
Cite item
Full Text
Abstract
Infant hypothalamic-chiasmatic gliomas demonstrate aggressive behavior and poor response to chemotherapy. Diencephalic syndrome is often the first and, for a long time, the only symptom of these tumors, which leads to diagnostic delay. Diencephalic syndrome has been reported as an adverse prognostic factor in pediatric low-grade gliomas. Alternative therapies such as novel molecular targeted therapies are particularly needed for these patients. Here we report two clinical cases of infants with KIAA1549–BRAF rearranged hypothalamic/chiasmatic gliomas who presented with diencephalic syndrome and progressed on standard chemotherapy. Treatment with the MEK inhibitor trametinib resulted in a significant reduction in tumor size and the normalization of the weight curve in both cases. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.
About the authors
L. I. Papusha
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
							Author for correspondence.
							Email: ludmila.mur@mail.ru
				                	ORCID iD: 0000-0001-7750-5216
				                																			                								
Ludmila I. Papusha, Cand. Med. Sci., a pediatric oncologist, Head of the Department of Optimization of CNS Tumor Therapy
117997, Moscow, Samory Mashela St., 1
Russian FederationA. A. Merishavyan
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Moscow
Russian FederationM. A. Zaytseva
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
																		                	ORCID iD: 0000-0003-2015-5790
				                																			                								
Moscow
Russian FederationV. A. Degtyarev
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Moscow
Russian FederationYu. A. Alymova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Moscow
Russian FederationA. E. Druy
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation; Research Institute of Medical Cell Technologies
																		                	ORCID iD: 0000-0003-1308-8622
				                																			                								
Moscow
Yekaterinburg
A. I. Karachunskiy
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
																		                	ORCID iD: 0000-0002-9300-198X
				                																			                								
Moscow
Russian FederationReferences
Supplementary files
 
				
			 
					 
						 
									
 
  
  
  Email this article
			Email this article 

